This study was approved by the Clinical Research Ethics Committee (CEIC) on 22 April 2010 (code PI-445) and enrolled 172 patients to evaluate the efficacy of the biologic agents administered for psoriasis in those years (anti-TNF-alpha: adalimumab, infliximab and etanercept and anti-IL-12/23: ustekinumab) [4]. This evidence concerns the gene TNF and psoriasis.